Skip to main content

Everything we do at Amylyx is centered around those living with diseases with high unmet needs and their loved ones. We are on a mission to discover and develop innovative treatments and to help support and create more moments for these communities.

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

Avexitide is a first-in-class GLP-1 receptor antagonist and FDA Breakthrough Therapy with highly statistically significant data and well-tolerated safety profile replicated across multiple clinical trials. Phase 3 program in avexitide in post-bariatric hypoglycemia (PBH) expected to begin in Q1 2025.​

In pursuit of more

Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.

Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.

Latest News